Vi­vo Cap­i­tal pitch­es $60M to bring Ar­row­head­'s RNAi meds to Chi­na via joint ven­ture

Gen­er­al­ly speak­ing, any biotech hop­ing to have a pres­ence in Chi­na has a num­ber of op­tions.

One could out-li­cense its drugs to one of the transpa­cif­ic play­ers set up ex­plic­it­ly to be a bridge be­tween West­ern med­i­cines and the Chi­nese mar­ket (as Blue­print did with Zai Lab); form a joint ven­ture with an es­tab­lished lo­cal phar­ma or CD­MO (as Kite did with Fo­s­un); or, more re­cent­ly, part­ner up with a next-gen­er­a­tion out­fit that of­fers a more flex­i­ble deal struc­ture (as ADC Ther­a­peu­tics did with Over­land).

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER